88 related articles for article (PubMed ID: 35557031)
1. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.
Pla-Juher H; Pardo M; Izquierdo ÀJ; Darder E; Carbó A; Munté E; Torres-Esquius S; Balmaña J; Lázaro C; Brunet JM; Barretina-Ginesta MP
Clin Transl Oncol; 2024 Apr; 26(4):1033-1037. PubMed ID: 37682500
[TBL] [Abstract][Full Text] [Related]
2. BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study.
Loizzi V; Mongelli M; Arezzo F; Romagno I; Cazzato G; Popescu O; Legge F; Trerotoli P; Silvestris E; Kardhashi A; Cormio G
Gynecol Obstet Invest; 2024; 89(2):87-94. PubMed ID: 38246147
[TBL] [Abstract][Full Text] [Related]
3. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.
Nebgen DR; Domchek SM; Kotsopoulos J; de Hullu JA; Crosbie EJ; Paramanandam VS; Brood-van Zanten MMA; Norquist BM; Guise T; Rozenberg S; Kurian AW; Pederson HJ; Yuksel N; Michaelson-Cohen R; Bober SL; da Silva Filho AL; Johansen N; Guidozzi F; Evans DG; Menon U; Kingsberg SA; Powell CB; Grandi G; Marchetti C; Jacobson M; Brennan DJ; Hickey M
BJOG; 2023 Nov; 130(12):1437-1450. PubMed ID: 37132126
[TBL] [Abstract][Full Text] [Related]
4. Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.
Shakya P; Bajracharya A; Shrestha S; Kharel S; Maharjan R; Shrestha AK
Ann Med Surg (Lond); 2022 Jan; 73():103158. PubMed ID: 34976386
[TBL] [Abstract][Full Text] [Related]
5. Germline
Carbajal-Mamani SL; Markham MJ; Santolaya-Forgas J; Castagno JC; Cardenas-Goicoechea J
Obstet Gynecol Sci; 2020 Mar; 63(2):205-208. PubMed ID: 32206661
[TBL] [Abstract][Full Text] [Related]
6. Ovarian Cancer Risk-Reduction and Screening in
DiSilvestro JB; Haddad J; Robison K; Beffa L; Laprise J; Scalia-Wilbur J; Raker C; Clark MA; Lokich E; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
J Womens Health (Larchmt); 2024 Mar; ():. PubMed ID: 38488054
[No Abstract] [Full Text] [Related]
7. Menopausal hormone therapy for BRCA mutation carriers: A case for precision medicine.
Kotsopoulos J; Narod SA
Maturitas; 2024 May; 183():107886. PubMed ID: 37980268
[No Abstract] [Full Text] [Related]
8. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.
Palaia I; Caruso G; Di Donato V; Turetta C; Savarese A; Perniola G; Gallo R; Giannini A; Salutari V; Bogani G; Tomao F; Giannarelli D; Gentile G; Musella A; Muzii L; Pignata S;
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38497108
[TBL] [Abstract][Full Text] [Related]
9. Risk-reducing decisions regarding germline
Abe A; Nomura H; Fusegi A; Yunokawa M; Ueki A; Habano E; Arakawa H; Kaneko K; Minoura Y; Inari H; Ueno T; Kanao H
J Med Genet; 2024 Mar; 61(4):392-398. PubMed ID: 38124001
[TBL] [Abstract][Full Text] [Related]
10. The pathogenic role of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition.
Yamazawa K; Sugano K; Tanakaya K; Inoue S; Murakami H; Nakashima M; Adachi M; Oki S; Makabe T; Yamashita H; Ueki A; Sasaoka A; Nakashoji A; Kinoshita T; Matsunaga T; Arai M; Nakamura S; Miyata H; Ikegami M; Mano H; Kohsaka S; Matsui A
Cancer Sci; 2023 Jul; 114(7):2993-3002. PubMed ID: 37067535
[TBL] [Abstract][Full Text] [Related]
11. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside.
Boussios S; Rassy E; Moschetta M; Ghose A; Adeleke S; Sanchez E; Sheriff M; Chargari C; Pavlidis N
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010882
[TBL] [Abstract][Full Text] [Related]
12. Differences in age at diagnosis of ovarian cancer for each
Sekine M; Enomoto T; Arai M; Den H; Nomura H; Ikeuchi T; Nakamura S;
J Gynecol Oncol; 2022 Jul; 33(4):e46. PubMed ID: 35557031
[TBL] [Abstract][Full Text] [Related]
13. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
Wang Y; Song Z; Zhang S; Wang X; Li P
Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
[TBL] [Abstract][Full Text] [Related]
14. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
[TBL] [Abstract][Full Text] [Related]
15. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
16. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
17. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
